Literature DB >> 11679570

Reduced susceptibility of Clostridium difficile to metronidazole.

J S Brazier, W Fawley, J Freeman, M H Wilcox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11679570     DOI： 10.1093/jac/48.5.741

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  26 in total

1.  Routine disc diffusion antimicrobial susceptibility testing of Clostridium difficile and association with PCR ribotype 027.

Authors:  H M Holt; T K Danielsen; U S Justesen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-30       Impact factor: 3.267

2.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  Can metronidazole still be used for treatment of Clostridium difficile infections?

Authors:  Haihui Huang; Carl Erik Nord
Journal:  Curr Infect Dis Rep       Date:  2009-01       Impact factor: 3.725

5.  Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection.

Authors:  L Alcalá; E Reigadas; M Marín; A Martín; P Catalán; E Bouza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-24       Impact factor: 3.267

6.  In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.

Authors:  T Peláez; L Alcalá; R Alonso; A Martín-López; V García-Arias; M Marín; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 7.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 8.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

9.  Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.

Authors:  Reeja Maria Cherian; Chunsheng Jin; Jining Liu; Niclas G Karlsson; Jan Holgersson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

10.  In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.